---
schema_version: "secwatch.filing_event.v1"
accession: "0000882095-22-000010"
form_type: "8-K"
ticker: "GILD"
cik: "0000882095"
company_name: "GILEAD SCIENCES, INC."
filed_at: "2022-04-28T23:59:59+00:00"
generated_at: "2026-06-26T03:47:27.939115+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Gilead Q1 revenue $6.6B (+3%), non-GAAP EPS $2.12 (+4%), GAAP EPS $0.02 due to $2.7B impairment

## Summary
- GAAP diluted EPS $0.02 vs $1.37 Q1 2021 due to $2.7B IPR&D impairment; non-GAAP EPS $2.12, +4% YoY.
- Biktarvy sales $2.2B (+18%), oncology sales $420M (+60%) led by Trodelvy $146M (+103%) and cell therapy $274M (+43%).
- Veklury sales $1.5B (+5%); HIV total $3.7B (+2%); HCV sales $399M (-22%).
- Updated GAAP EPS guidance to $3.00-$3.50 from $4.70-$5.20; non-GAAP EPS and revenue guidance unchanged.
- Cash $6.8B; operating cash flow $1.8B includes $1.25B legal settlement; $725M Arcus opt-in payment, $352M buybacks.

## SEC filing metadata
- accession: 0000882095-22-000010
- form_type: 8-K
- ticker: GILD
- cik: 0000882095
- company_name: GILEAD SCIENCES, INC.
- filed_at: 2022-04-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882095/000088209522000010/0000882095-22-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882095/000088209522000010/gild-20220428.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000882095-22-000010
- JSON: https://secwatch.observer/filing/0000882095-22-000010.json
- Plain text: https://secwatch.observer/filing/0000882095-22-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.